장기간 또는 반복 노출되면 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킬 수 있음
특정 표적장기 독성 - 반복 노출
구분 2
경고
P260, P314, P501
예방조치문구:
P260
분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P261
분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P264
취급 후에는 손을 철저히 씻으시오.
P264
취급 후에는 손을 철저히 씻으시오.
P272
작업장 밖으로 오염된 의복을 반출하지 마시오.
P280
보호장갑/보호의/보안경/안면보호구를 착용하시오.
P302+P352
피부에 묻으면 다량의 물로 씻으시오.
P305+P351+P338
눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P314
불편함을 느끼면 의학적인 조치·조언을 구하시오.
P321
(…) 처치를 하시오.
P333+P313
피부자극성 또는 홍반이 나타나면 의학적인 조치·조언를 구하시오.
P363
다시 사용전 오염된 의류는 세척하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
Daclatasvir Dihydrochloride C화학적 특성, 용도, 생산
개요
Daclatasvir dihydrochloride is a hepatitis C virus nonstructural
5A (NS5A) replication complex inhibitor which was first approved
in Japan for the treatment of genotype 1 HCV patients who fail to
respond to interferon plus ribavirin. The drug has also been
approved for patients with untreated, chronic HCV who are eligible for interferon. Additionally, in Europe, daclatasvir was approved for
use in combination with other products across genotype 1–4 HCV.
Daclatasvir was discovered and developed by Bristol–Myers Squibb
and a fascinating account describing the initiation of the program
from a phenotypic screen and the medicinal chemistry strategy
leading to the discovery of the compound has been recently
reported.
화학적 성질
Daclatasvir dihydrochloride is white to yellow powder. It is freely soluble in water (>700 mg/mL). The solubility is strongly pH-dependent and the solubility is high at low pH values.
용도
Daclatasvir Dihydrochloride is the dihydrochloride salt form of daclatasvir, an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Daclatasvir is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Daclatasvir should never be used without sofosbuvir. Daclatasvir and sofosbuvir may also be used with another antiviral medication (ribavirin).
정의
ChEBI: Daclatasvir hydrochloride is a hydrochloride obtained by combining daclatasvir with two molar equivalents of hydrochloric acid. It is a potent inhibitor of nonstructural protein 5A and is used for treatment of hepatitis C. It has a role as an antiviral drug and a nonstructural protein 5A inhibitor. It contains a daclatasvir(2+).
Mode of action
Daclatasvir is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir binds to the N-terminus of NS5A and inhibits both viral RNA replication and virion assembly.